Obesity drugs enter their second act

Lilly raises the ceiling again

Eli Lilly makes medicines across several disease areas, but obesity has become its main growth engine. Zepbound already made it the company to beat. Now retatrutide, its next-generation weekly injection, has raised expectations again.

Retatrutide is known as a triple agonist. In plain English, it copies three body signals involved in appetite, blood sugar and energy use: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. The full names can now be safely parked. The key point is simpler: Lilly is trying to pull several biological levers at once.

The latest data showed average weight loss of 28.3% over 80 weeks at the highest tested dose, with a longer extension showing just above 30% in a selected group. The lower dose also drew attention because it delivered strong weight loss with fewer side-effect concerns. That matters because the best drug on paper is not always the best drug in real life. Patients need to stay on it.

Lilly also showed benefits in sleep apnoea, knee pain and type 2 diabetes. That may prove more important than the headline weight-loss number. If obesity drugs can also reduce related health problems, they become less like cosmetic products and more like broad healthcare platforms.

Novo still owns an important front door

Novo Nordisk is not standing still. The Danish company has more than 100 years of experience in diabetes care, and Wegovy turned it into the first global obesity-drug champion. Its challenge now is to prove it can defend that position in a market moving quickly.

Novo’s strongest recent card is the Wegovy pill. The company said prescriptions surpassed 3 million in the United States since launch in January 2026, with more than 80% of new starts coming from people new to glucagon-like peptide-1 (GLP-1) therapy. That matters because the Wegovy pill is not only pulling patients away from injections. It appears to be bringing new people into the category.

Convenience matters. Some people dislike injections. Some need a maintenance option after weight loss. Others may accept less dramatic results for a lower price or easier routine. In healthcare, the best product is often the one people actually take.

Novo also presented new data for CagriSema, a weekly injection combining semaglutide with an amylin analogue. Amylin is another hormone linked to appetite and blood sugar control. In type 2 diabetes trials, CagriSema reduced both blood sugar and body weight. The data helps Novo show that it still has serious science behind its pipeline.

The rest of the field enters the kitchen

The obesity market is now too large for only two companies. More than 1 billion people worldwide live with obesity, according to the World Health Organization. That does not mean everyone will use these drugs, but it explains why the industry is rushing in.

AstraZeneca is one of the more interesting challengers. Its experimental pill, elecoglipron, helped patients lose up to 11.8% of body weight over 36 weeks in a mid-stage trial. That is below Lilly’s strongest injection data, but AstraZeneca is trying to compete differently: through combinations, cardiometabolic expertise, price and emerging-market reach.

Other companies are trying to win where Lilly and Novo may not be perfect. Some are testing monthly injections, others are developing gentler amylin-based drugs, and several are working on treatments that may better preserve muscle mass. That matters because not all weight loss is equal.

Zealand Pharma’s sharp fall after tolerability concerns around a partnered obesity drug is a useful reminder of the challenge. In this market, a big weight-loss number can open the door, but side effects, dropout rates and patient comfort decide how long that door stays open.

Risks to watch

The first risk is tolerability. Nausea, vomiting and treatment dropouts can limit adoption, especially if patients must stay on therapy for years. Early warning signs include high discontinuation rates in trials and weak refill data after launch.

The second risk is pricing and access. These medicines can be expensive, and health systems will not pay unlimited bills with a smile. Watch insurance coverage, government negotiations and evidence that drugs reduce wider healthcare costs.

The third risk is competition. New entrants could pressure prices, and pipeline setbacks could quickly change market expectations.

For Lilly, the risk is that its share price already reflects strong confidence in Zepbound, retatrutide and the wider pipeline. For Novo, the valuation looks less demanding after its sharp decline, but investors want proof that Wegovy pills, CagriSema and future combinations can rebuild confidence as competition intensifies.

Investor playbook

• Track adherence, not only weight loss. A medicine only creates value if patients keep using it.
• Separate science from sales. Strong trial data still needs manufacturing, access and doctor adoption.
• Watch the pipeline as a portfolio. One drug is useful. Several options create resilience.
• Treat obesity exposure as healthcare growth, not a straight-line story. Competition will bring setbacks.

Beyond the bathroom scale

The obesity drug race began with the bathroom scale. That made sense. Weight loss is easy to understand, easy to measure and easy to turn into headlines. But the market is now growing up. The next winners may be the companies that combine strong results with fewer side effects, easier use, wider health benefits, better access and a deeper pipeline.

Lilly currently looks like the pace-setter. Novo still has powerful commercial reach and scientific depth. Rivals are no longer background music. For investors, the lesson is simple: the scale still matters, but it may not decide the final winner.

The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.

The author does not hold any position in the financial instruments mentioned at the time of publication.